Treatment with NMDA receptor antagonists does not affect developmental changes in NMDA receptor properties in vivo
References (50)
- et al.
N-methyl-d-aspartate promotes survival of cerebellar granule cells in culture
Neuroscience
(1988) - et al.
Changes in voltage dependence of NMDA currents during development
Neurosci. Lett.
(1988) - et al.
Developmental increase in the sensitivity to magnesium of NMDA receptors on CA1 hippocampal pyramidal cells
Dev. Brain Res.
(1990) - et al.
Developmental changes in the voltage-dependence of neocortical NMDA responses
Dev. Brain Res.
(1994) - et al.
Intracellular Ca2+ and N-methyl-d-aspartate-stimulated neuritogenesis in rat cerebellar granule cell cultures
Dev. Brain Res.
(1992) - et al.
Chronic neonatal blockade of NMDA receptor does not affect polyamine metabolism but results in altered response to the excitotoxic induction of ornithine decarboxylase
Neurochem. Int.
(1994) - et al.
Chronic neonatal blockade of N-methyl-d-aspartate receptor by CGP39551 increases dopaminergic function in adult rat
Neuroscience
(1994) - et al.
Structural, neurochemical and behavioural consequences of neonatal blockade of NMDA receptor through chronic treatment with CGP39551 or MK-801
Dev. Brain Res.
(1993) - et al.
Long-lasting effects of chronic neonatal blockade of N-methyl-d-aspartate receptor through the competitive antagonist CGP39551 in rats
Neuroscience
(1994) - et al.
Seizure-like activity and cellular damage in rat hippocampal neurons in cell culture
Neuron
(1989)
In vivo binding and autoradiographic imaging of (+)-3- [125I]Iodo-MK-801 to the NMDA receptor-channel complex in rat brain
Nucl. Med. Biol.
(1992)
The effect of age on binding of MK-801 in the cat visual cortex
Dev. Brain Res.
(1991)
Chronic neonatal MK-801 treatment results in an impairment of spatial learning in the adult rat
Brain Res.
(1992)
Chronic neonatal NMDA receptor blockade with MK-801 alters monoamine metabolism in adult rat
Neurosci. Lett.
(1992)
Hippocampal neuronal responsiveness to NMDA agonists and antagonists in the adult rat neonatally treated with MK-801
Brain Res.
(1992)
The ontogeny of excitatory amino acid receptors in rat forebrain—I. N-methyl-d-aspartate and quisqualate receptors
Neuroscience
(1990)
Glutamate dehydrogenase improves binding of [3H]CGP39653 to NMDA receptor in the autoradiographic assay
J. Neurosci. Meth.
(1993)
MK-801 protects the neonatal brain from hypoxicischemic damage
Eur. J. Pharmac.
(1987)
Differential ontogenetic development of three receptors comprising the NMDA receptor/channel complex in the rat hippocampus
Exp. Neurol.
(1990)
MK-801 pretreatment enhances N-methyl-d-aspartate mediated brain injury and increases brain N-methyl-d-aspartate recognition site binding in rats
Neuroscience
(1990)
Physiological and pathophysiological roles of excitatory amino acids during central nervous system development
Brain Res. Rev.
(1990)
Analysis of radioligand binding experiments: a collection of computer programs for the IBM PC
J. Pharmac. Meth.
(1985)
Chronic administration of NMDA antagonists induces D2 receptor synthesis in rat striatum
Mol. Brain Res.
(1992)
[3H]MK-801 binding sites in neonate rat brain
Brain Res.
(1989)
Reduced sensitivity of the N-methyl-d-aspartate component of synaptic transmission to magnesium in hippocampal slices from immature rats
Dev. Brain Res.
(1990)
Cited by (7)
Early brain development disruption from NMDA receptor hypofunction: Relevance to schizophrenia
2007, Brain Research ReviewsCitation Excerpt :Facchinetti et al. (1993) found that chronic perinatal MK-801 treatment had no effect on NMDA receptor binding. Similarly, Van Lookeren Campagne et al. (1995) found that this treatment did not alter NMDA receptor binding properties in membrane preparations. Conversely, acute perinatal MK-801 administration increased expression of NMDA receptor subunits, especially NR2A, in the cortex, hippocampus and striatum (Wilson et al., 1998).
Modulation by magnesium of N-methyl-D-aspartate receptors in developing human brain
1998, Archives of Disease in Childhood: Fetal and Neonatal Edition
- ∗
Present address: F. Hoffmann-La Roche Ltd, PRPN, Bau 69/402, Grenzacherstrasse 124, CH-4002 Basel, Switzerland.
- ‡
Present address: University of California, Irvine, IRU in Brain Aging, Biosciences II, 2205 Irvine, CA 92717, U.S.A.
Copyright © 1995 Published by Elsevier Ltd.